Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated ...

Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1), a genetic disorder ...

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

The team showed promising ... Ultrasensitive Liquid Biopsy Tech Spots Cancer Earlier Than Standard Methods June 14, 2024 — An artificial intelligence-powered method for detecting tumor DNA in ...

Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

Aditxt, Inc. ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized ...

Columnist Patrick Moeschen was given an incorrect diagnosis of Becker muscular dystrophy, years before learning he actually ...

Dyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1. Shares down about 22% in early trade. DYNE-101 continued ...

When Raniya Scott was just two years old, her world changed with an unexpected diagnosis: Duchenne muscular dystrophy (DMD), ...

For example, if chest pain does not last longer than several minutes, it might be muscular. If the pain feels tender or worsens when you press on the area, a chest injury or pulled muscle may be ...